Crossmark

Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer

Crossref DOI link: https://doi.org/10.1038/s41467-023-42736-y

Published Online: 2023-11-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saatci, Ozge https://orcid.org/0000-0002-0124-044X
Cetin, Metin

Uner, Meral https://orcid.org/0000-0001-9927-1246
Tokat, Unal Metin https://orcid.org/0000-0003-0026-368X
Chatzistamou, Ioulia https://orcid.org/0000-0002-6632-8469
Ersan, Pelin Gulizar https://orcid.org/0000-0003-3637-4090
Montaudon, Elodie

Akyol, Aytekin

Aksoy, Sercan https://orcid.org/0000-0003-4984-1049
Uner, Aysegul

Marangoni, Elisabetta https://orcid.org/0000-0002-3337-6448
Sajish, Mathew https://orcid.org/0000-0001-6715-5953
Sahin, Ozgur https://orcid.org/0000-0002-8033-7089
License Information

Text and Data Mining valid from 2023-11-02

Version of Record valid from 2023-11-02
More Information

Article History

Received: 28 February 2023

Accepted: 26 September 2023

First Online: 2 November 2023

Competing interests

: O. Sahin is the co-founder and manager of OncoCube Therapeutics LLC, developing TACC3 inhibitors, and the founder and president of LoxiGen, Inc, developing lysyl oxidase inhibitors. The other authors declare no potential conflicts of interest.

Document is current

Any future updates will be listed below